Press Releases

AstraZeneca R&D Boston today announced a significant expansion of its research program into Helicobacter pylori (H. pylori) infection and associated gastrointestinal diseases. The Scriabin research initiative will direct additional scientific resources toward understanding the complex interactions between H. pylori and the human gastric mucosa, with the goal of developing more effective eradication therapies and identifying novel drug targets.

"H. pylori remains one of the most clinically significant infectious agents worldwide, directly responsible for the majority of peptic ulcer disease and representing the primary microbial risk factor for gastric cancer," said the program's scientific director. "By bringing together our expertise in acid physiology, microbiology, and drug development, we believe we can make meaningful contributions to how this infection is diagnosed, treated, and ultimately prevented."

The expanded program will focus on three complementary research areas: (1) understanding how H. pylori virulence factors like CagA and VacA drive host cell damage and immune evasion; (2) investigating pharmacological strategies to enhance antibiotic efficacy through optimized acid suppression; and (3) exploring novel therapeutic targets in the bacterium's metabolic and regulatory pathways that could be exploited by future drug candidates.

AstraZeneca's longstanding expertise in proton pump inhibitor pharmacology — stemming from the development of omeprazole and esomeprazole — provides a strong scientific foundation for this research program. PPIs are a cornerstone of all current H. pylori eradication regimens, and deeper understanding of the relationship between acid suppression and antibiotic efficacy may help optimize existing treatments while informing the development of next-generation therapeutics.

Scientists from the AstraZeneca R&D Boston Scriabin research program presented a series of scientific communications at an international symposium on Helicobacter pylori and related gastrointestinal diseases, sharing new data on the bacterium's virulence mechanisms and the pharmacological determinants of successful eradication therapy.

Key presentations from the Scriabin team addressed the role of the cagA pathogenicity island in modulating host cell signaling pathways and the downstream consequences for gastric epithelial integrity. Additional data examined the pharmacokinetic and pharmacodynamic factors that determine optimal PPI dosing for H. pylori eradication, with particular focus on the relationship between intragastric pH elevation and antibiotic stability and bioavailability at the site of infection.

"International scientific meetings provide a critical forum for sharing emerging data and aligning research directions with the global scientific community working on H. pylori," noted the Scriabin program's lead researcher. "The data we presented support our mechanistic understanding and will help guide the prioritization of therapeutic targets in our ongoing drug discovery programs."

The symposium also featured discussions on the growing challenge of antibiotic resistance in H. pylori, with resistance to clarithromycin and metronidazole increasing in many populations worldwide. This resistance landscape underscores the urgency of developing novel eradication strategies that can overcome existing resistance mechanisms.

AstraZeneca R&D Boston announced a collaborative research agreement designed to accelerate progress in Helicobacter pylori research by combining the company's pharmaceutical expertise with complementary scientific capabilities from academic and clinical research partners.

The collaboration will focus on developing improved diagnostic tools for H. pylori detection and antimicrobial susceptibility testing, as well as advancing the mechanistic understanding of treatment failure and antibiotic resistance. By integrating AstraZeneca's pharmacological expertise with clinical microbiology research capabilities, the program aims to address important gaps in current knowledge about why eradication rates vary substantially between patient populations.

H. pylori eradication rates with standard therapies have declined in many regions due to rising antibiotic resistance, highlighting the need for improved diagnostic testing to guide therapy selection and novel treatment regimens that can overcome resistance. The collaborative program will generate data to inform evidence-based treatment guidelines and support the development of next-generation therapeutic strategies.

The agreement reflects AstraZeneca's commitment to addressing the significant unmet medical need represented by H. pylori infection and its serious complications, including peptic ulcer disease and gastric cancer, which together cause substantial morbidity and mortality worldwide.